Francisco H. Cruzalegui
Croissy-sur-seine, 78290, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.
Journal: Frontiers in immunology
Published: March 02, 2024
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Journal: Journal of medicinal chemistry
Published: June 18, 2021
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Journal: Journal of medicinal chemistry
Published: May 12, 2021
Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Journal: Molecular cancer therapeutics
Published: February 14, 2018
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Journal: Oncotarget
Published: February 05, 2018
LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers.
Journal: Oncotarget
Published: January 18, 2018
Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 08, 2017
Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Journal: ChemMedChem
Published: October 24, 2016
Defining actionable mutations for oncology therapeutic development.
Journal: Nature reviews. Cancer
Published: April 27, 2016
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Journal: Molecular cancer therapeutics
Published: August 19, 2015
TIPIN depletion leads to apoptosis in breast cancer cells.
Journal: Molecular oncology
Published: October 23, 2014
Last Updated: 09/26/2026